Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed 43 enrolled Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Safingol may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of safingol when given with cisplatin in treating patients with locally advanced or metastatic solid tumors.

Timeline

Start: 2004-03
Primary completion: 2009-02
Completion: 2009-02

Publications

Results Dickson MA, Carvajal RD, Merrill AH Jr, Gonen M, Cane LM, Schwartz GK. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2484-92. doi: 10.1158/1078-0432.CCR-10-2323. Epub 2011 Jan 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	60 mg/m2	Intravenous
Subject	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Subject	Safingol	Small molecule	840 mg/m2	Intravenous

Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Summary

Timeline

Publications

Drugs

Indications